Background
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel and Carboplatin, have enhanced inhibition on non-small-cell lung cancer.• Phosphatidylserine and the human brain., PMID:25933483• The distribution and function of phosphatidylserine in cellular membranes., PMID:20192774• Phosphatidylserine transport in cell life and death., PMID:37413778• Phosphatidylserine., PMID:10541030• Phosphatidylserine: A Novel Target for Ischemic Stroke Treatment., PMID:39456225• Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis., PMID:33539192• Phosphatidylserine externalization as immune checkpoint in cancer., PMID:38573347• Phosphatidylserine: A comprehensive overview of synthesis, metabolism, and nutrition., PMID:39097133• Dynamics of phagocytosis mediated by phosphatidylserine., PMID:36281986• Flagging fusion: Phosphatidylserine signaling in cell-cell fusion., PMID:33581114